Expertise in
3
conditions

Adalberto S. Rubin

Santa Casa De Misericórdia De Porto Alegre
Porto Alegre, RS, BR 
Expertise in
3
conditions
Santa Casa De Misericórdia De Porto Alegre
Porto Alegre, RS, BR 
OverviewLocationsClinical Research

Overview

Adalberto Rubin practices in Porto Alegre, Brazil. Mr. Rubin is highly rated in 3 conditions, according to our data. His top areas of expertise are Asthma, Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, RS, Brazil
Other Locations
Irmandade Santa Casa De Misericórdia De Porto Alegre, Av. Independência, 75, Independencia, MG 90020160, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
An Observational, Cross-sectional Study of Primary Data Collection to Describe Symptoms Over 24 Hours and Their Relationship With Adherence to Respiratory Treatment, Direct Costs and PRO in Stable COPD Patients in Brazil.
An Observational, Cross-sectional Study of Primary Data Collection to Describe Symptoms Over 24 Hours and Their Relationship With Adherence to Respiratory Treatment, Direct Costs and PRO in Stable COPD Patients in Brazil.
Enrollment Status: Completed
Publish Date: June 28, 2019
View 2 Less Clinical Trials

37 Total Publications

Baseline characteristics of patients from the Brazilian Severe Asthma Registry: the REBRAG study.
Baseline characteristics of patients from the Brazilian Severe Asthma Registry: the REBRAG study.
Journal: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
Published: January 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rubin's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile